

Supplemental Table S2. Changes in Clinical Characteristics between at the End of GH Treatment and at Re-Evaluation

Characteristic	No.	At the end of GH treatment	At re-evaluation	P value
Age, yr	187	15.6±2.5	18.9±2.9	-
Height, cm	187	158.3±11.6	163.9±9.1	<0.001
Weight, kg	185	56.4±14.1	65.0±15.2	<0.001
Body mass index, kg/m ²	185	22.3±4.2	24.1±4.8	<0.001
Height Z-score	187	-0.92±1.30	-0.70±1.48	<0.001
Weight Z-score	185	-0.14±1.44	0.31±1.67	<0.001
Body mass index Z-score	185	0.37±1.45	0.74±1.67	<0.001
Overweight and/or obesity	185	61 (33.0)	88 (47.6)	<0.001
IGF-1, µg/L	155	314.9±227.3	81.1±69.5	<0.001
IGFBP-3, µg/L	78	3,227.9±1,531.8	1,777.4±601.2	<0.001
Fasting plasma glucose, mg/dL	126	91.9±12.2	87.3±11.8	0.002
Glycated hemoglobin, %	77	5.5±0.8	5.4±0.4	0.113
Prediabetes/diabetes	73	37 (50.7)	30 (41.1)	0.210
Total cholesterol, mg/dL	137	170.6±34.1	184.7±33.6	<0.001
Triglyceride, mg/dL	75	141.8±71.2	149.9±75.4	0.402
HDL cholesterol, mg/dL	38	47.8±12.6	42.4±11.9	0.022
LDL cholesterol, mg/dL	38	102.6±29.7	117.6±38.3	0.015
Non-HDL cholesterol, mg/dL	38	128.6±25.2	140.3±37.4	0.025
Dyslipidemia	56	46 (82.1)	44 (78.6)	0.774

Values are expressed as mean±standard deviation or number (%).

GH, growth hormone; IGF-1, insulin-like growth factor-1; IGFBP-3, IGF-binding protein-3; HDL, high-density lipoprotein; LDL, low-density lipoprotein.